DGAP-News: Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology

PRESS RELEASE
27 September 2018
/

Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology

- Expedeon's proprietary colloidal gold to be used for manufacturing of diagnostic lateral flow assays

- Expedeon's InnovaCoat^(R) GOLD to be assessed for increasing sensitivity of marketed assays

Heidelberg, Germany and Cambridge, UK, 27 September 2018 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has signed a three year supply agreement for its colloidal gold with Malaysia-based Reszon Diagnostics International Sdn. Bhd. (part of Revongen Corporation) ("Reszon"), a developer and manufacturer of innovative in vitro diagnostics (IVD) rapid test kits, and ELISA kits. Reszon operates globally covering Asia, Middle East, sub-Saharan Africa, and the USA.

Under the terms of the agreement, Expedeon will supply Reszon with its proprietary colloidal gold, an aqueous suspension of spherical metallic nanoparticles manufactured to the highest standard, providing high efficiency antibody binding for maximum sensitivity. Reszon will use the gold nanoparticles for manufacturing of its diagnostic lateral flow assays (LFAs). The company will also be testing Expedeon's InnovaCoat^(R) GOLD nanoparticles, to increase the sensitivity of LFA which are already on the market. InnovaCoat^(R) GOLD nanoparticles have a proprietary surface coating which covalently binds antibodies or proteins to form highly stable conjugates. The technology is fully scalable and stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.

Dr. Heikki Lanckriet, CEO and CSO of Expedeon, commented: "This agreement is the second just this month for our colloidal gold in Asia, further validating Expedeon as a global supplier for the diagnostics industry. The adoption of our colloidal gold and InnovaCoat^(R) GOLD products by Reszon Diagnostics exemplifies the increased reach Expedeon is seeing as a key provider of materials and services to the diagnostics industry. We are confident that this represents the start of a successful and expanding relationship with Reszon and its parent company Revongen."

For a high resolution image, please contact MC Services or Zyme Communications.

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu
Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Phone: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###